High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database

• Published in: Drug metabolism and pharmacokinetics Vol. 49; p. 100486
• Main Authors: Adachi, Koichiro, Ohyama, Katsuhiro, Tanaka, Yoichi, Sato, Tasuku, Murayama, Norie, Shimizu, Makiko, Saito, Yoshiro, Yamazaki, Hiroshi
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2023
• Subjects: Adverse Drug Reaction Reporting Systems; Atorvastatin - adverse effects; CYP3A4.1; CYP3A4.16; CYP3A5; Cytochrome P-450 CYP3A Inhibitors - adverse effects; Drug Interactions; East Asian People; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Pharmacokinetic modeling; CYP3A4.16; CYP3A4.1; CYP3A5; Pharmacokinetic modeling
• ISSN: 1347-4367; 1880-0920; 1880-0920
• DOI: 10.1016/j.dmpk.2022.100486

Drug interactions between atorvastatin and cytochrome P450 (P450) 3A substrates/inhibitors lead to an increased incidence of skeletal muscle or hepatic toxicity. However, in this survey, among 483 Japanese subjects administered atorvastatin alone, more than half (258) experienced statin intolerance and were unable to continue using the drug. Although many factors underly atorvastatin toxicity, the intrinsic clearance rate might be a contributing causal factor. The impaired P450 3A4 p.Thr185Ser variant, CYP3A4∗16 (rs12721627), has been identified in East Asians with an allele frequency of 2.2%. Pharmacokinetically modeled plasma concentrations of atorvastatin increased after a virtual oral dose of 40 mg in CYP3A4∗16 homozygotes; the maximum concentration and area under the concentration curve, respectively, were 3.3-fold and 4.2-fold those in subjects homozygous for CYP3A4∗1. In subjects with CYP3A4∗16/∗16, the virtual hepatic concentrations of atorvastatin after daily doses of 10 mg for a week were similar to or higher than the plasma concentrations. These results suggest that the estimated high virtual plasma and hepatic exposures obtained by pharmacokinetic modeling in subjects harboring impaired allele CYP3A4∗16 may be one of the causal factors for statin intolerance in a manner similar to the well-known drug interactions caused by co-administrations of CYP3A inhibitors. [Display omitted]